K
Kreshnik Zejnullahu
Researcher at Harvard University
Publications - 21
Citations - 8945
Kreshnik Zejnullahu is an academic researcher from Harvard University. The author has contributed to research in topics: Erlotinib & Epidermal growth factor receptor. The author has an hindex of 13, co-authored 21 publications receiving 8351 citations. Previous affiliations of Kreshnik Zejnullahu include Howard Hughes Medical Institute & California Pacific Medical Center.
Papers
More filters
Journal ArticleDOI
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman,Kreshnik Zejnullahu,Tetsuya Mitsudomi,Youngchul Song,Courtney Hyland,Joon Oh Park,Neal I. Lindeman,Christopher-Michael Gale,Xiaojun Zhao,James J. Christensen,Takayuki Kosaka,Alison J. Holmes,Andrew M. Rogers,Federico Cappuzzo,Tony Mok,Charles Lee,Bruce E. Johnson,Lewis C. Cantley,Pasi A. Jänne +18 more
TL;DR: It is proposed that MET amplification may promote drug resistance in other ERBB-driven cancers as well after it was found that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)–dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.
Journal ArticleDOI
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke,Kreshnik Zejnullahu,Yi-Long Wu,Youngchul Song,Dora Dias-Santagata,Eugene Lifshits,Luca Toschi,Andrew H. Rogers,Tony Mok,Lecia V. Sequist,Neal I. Lindeman,Carly Murphy,Sara Akhavanfard,Beow Y. Yeap,Yun Xiao,Yun Xiao,Marzia Capelletti,A. John Iafrate,Charles Lee,James G. Christensen,Jeffrey A. Engelman,Pasi A. Jänne +21 more
TL;DR: Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy is highlighted.
Journal ArticleDOI
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi Koivunen,Craig H. Mermel,Kreshnik Zejnullahu,Carly Murphy,Eugene Lifshits,Alison J. Holmes,Hwan Geun Choi,Jhingook Kim,Derek Y. Chiang,Roman K. Thomas,Jinseon Lee,William G. Richards,David J. Sugarbaker,Christopher T. Ducko,Neal I. Lindeman,J. Paul Marcoux,Jeffrey A. Engelman,Nathanael S. Gray,Charles Lee,Matthew Meyerson,Pasi A. Jänne +20 more
TL;DR: EML4-ALK was detected more frequently in NSCLC patients who were never or light (<10 pack-years) cigarette smokers compared with current/former smokers, and TAE684 inhibited the growth of one of three EML4-alk-containing cell lines in vitro and in vivo, inhibited Akt phosphorylation, and caused apoptosis.
Journal ArticleDOI
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Jeffrey A. Engelman,Kreshnik Zejnullahu,Christopher Michael Gale,Eugene Lifshits,Gonzales Andrea,Takeshi Shimamura,Feng Zhao,Patrick Vincent,George N. Naumov,James E. Bradner,Irene W. Althaus,Leena Gandhi,Geoffrey I. Shapiro,James M. Nelson,John V. Heymach,Matthew Meyerson,Kwok-Kin Wong,Pasi A. Jänne +17 more
TL;DR: Results from these studies show that PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo, and these preclinical evaluations support further clinical development of PF00 299804 for cancers with mutations and/or amplifications of ERBB family members.
Journal ArticleDOI
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka,Kreshnik Zejnullahu,Isamu Okamoto,Taroh Satoh,Federico Cappuzzo,John Souglakos,Dalia Ercan,Andrew H. Rogers,Massimo Roncalli,Masayuki Takeda,Yasuhito Fujisaka,Juliet Philips,Toshio Shimizu,Osamu Maenishi,Yonggon Cho,Jason Sun,Annarita Destro,Koichi Taira,Koji Takeda,Takafumi Okabe,Jeffrey Swanson,Hiroyuki Itoh,Minoru Takada,Eugene Lifshits,Kiyotaka Okuno,Jeffrey A. Engelman,Ramesh A. Shivdasani,Ramesh A. Shivdasani,Kazuto Nishio,Masahiro Fukuoka,Marileila Varella-Garcia,Kazuhiko Nakagawa,Pasi A. Jänne,Pasi A. Jänne +33 more
TL;DR: Examination of cellular data with patient experience improves confidence that concomitant treatment of certain lung, head and neck, or colorectal cancers with cetuximab and an anti-ERBB2 drug may prevent or delay the development of drug resistance.